As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Subjects with Severe Hemophilia A or B

Clinical Trial Title: 
A multicenter, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous and/or intravenous PF-06741086 in subjects with severe hemophilia A or B.
Clinical Trial Protocol ID: 
16090605
Clinical Trial Investigator Name: 
Lisa Boggio, MD
Clinical Trial Protocol Description: 

Nineteen office clinic visits over 5 months.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are age 18-64 years old.
  • Have hemophilia A or B.
  • Have had 6 bleeds within 6 months.
  • Have on demand (PRN) factor usage.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Lisa Boggio, MD